In a report published Wednesday, Mizuho Securities USA analyst Mario Corso reiterated a Buy rating on Auxilium Pharmaceuticals AUXL, and raised the price target from $33.00 to $37.00.
In the report, Mizuho Securities USA noted, “Last night's ENDP bid of $28.10/AUXL share is below 2014 high and our standalone valuation, implying term revisions likely. Inclusion of restructuring cost savings/QLT tax benefits raised numbers dramatically in 2015+, with our 2014 slightly lower on revenue conservatism, DCF target to $37 from $33. We do not expect major negatives from Wednesday's testosterone FDA panel, but CV studies could be requested and/or approved indication narrowed, but little effect with Testim now <10% of 2015 revenue vs. 50% in 2013, reflecting focus on growth drivers Xiaflex, Stendra,”
Auxilium Pharmaceuticals closed on Tuesday at $21.52.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in